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 Autophagic Cell Death and Cancer 
Chemotherapeutics 
 Shigeomi  Shimizu 
 Abstract  Autophagy usually functions in cell-protective events. However, it may 
also be utilized as a cell-suicide mechanism, which is known as “autophagic cell 
death.” Autophagic cell death is frequently induced in cells that lack apoptotic 
machinery, such as p53-deﬁ cient cancer cells. Therefore, small compounds that 
activate autophagic cell death are good candidates for anticancer chemotherapeutics 
to combat p53-deﬁ cient cancers. This chapter focuses on recent advances in autophagy/
autophagic cell death and their relationship with tumorigenesis. 
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 Apoptosis and Other Types of Cell Death 
 Apoptosis is a form of programmed cell death (PCD) and its molecular basis is well 
understood. Mammalian cells possess two apoptotic signaling pathways, which are 
known as the intrinsic and extrinsic pathways. In the intrinsic pathway, mitochon-
dria play a crucial role by increasing membrane permeability to release several 
apoptogenic molecules (e.g., cytochrome  c , Smac, and Omi) into the cytoplasm. 
After its release, cytochrome  c associates with Apaf-1, which activates the caspase 
cascade to execute apoptotic cell death. Smac and Omi accelerate caspase activation 
by inhibiting IAP family proteins that function as endogenous caspase inhibitors. 
The Bcl-2 family proteins are well-characterized regulators of apoptosis, which 
directly modulate mitochondrial membrane permeability [ 1 ]. This family of proteins 
contains anti-apoptotic members, such as Bcl-2 and Bcl-x L , and pro-apoptotic members, 
including multidomain Bax and Bak, as well as numerous BH3-only proteins. 
Multidomain pro-apoptotic Bax and Bak are functionally redundant and play a 
direct role in increasing mitochondrial membrane permeability, thereby leading to 
the release of apoptogenic proteins. BH3-only proteins function as death transducers 
by activating Bax/Bak or inactivating anti-apoptotic Bcl-2 family members [ 1 ]. 
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 Until 10 years ago, the evidence indicated that apoptosis is the primary mediator 
of physiological and pathological cell death. However, a detailed analysis of Bax/
Bak double-knockout mice with a totally inhibited intrinsic apoptotic pathway 
showed that PCD mainly proceeds normally in organisms that lack apoptosis [ 2 ,  3 ]. 
These ﬁ ndings encouraged researchers to identify other pathways of PCD, i.e., non- 
apoptotic cell death. Several types of non-apoptotic cell death have been elucidated, 
such as programmed necrosis [ 4 ] and autophagic cell death [ 5 ]. Previously, necrosis 
was considered to be a form of accidental cell death due to physicochemical stress-
ors but recent evidence has demonstrated the existence of regulated (or programmed) 
necrosis. Regulated necrosis is a genetically controlled form of cell death, which is 
characterized morphologically by cytoplasmic granulation and cellular swelling. 
Necroptosis is one of the best-characterized types of programmed necrosis, which 
is activated by several kinases, including RIP1, RIP3, and MLKL, whereas it is 
inhibited by the small compound necrostatin-1 [ 6 ]. Autophagic cell death is another 
type of non-apoptotic cell death that occurs via autophagy activation. Autophagy 
has long been considered a cell-protective mechanism but recent evidence indicates 
that the hyperactivation of autophagy is sometimes utilized as a cell-suicide mecha-
nism. This chapter summarizes the current knowledge of autophagy and autophagic 
cell death. 
 Autophagy 
 Autophagy is a catabolic process that digests cellular contents within lysosomes. 
Autophagy is a low-level constitutive function, which is accelerated by a variety of 
cellular stressors such as nutrient starvation, DNA damage, and organelle damage. 
Autophagy is a protective mechanism that facilitates the degradation of superﬂ uous 
or damaged cellular constituents, although hyperactivation of autophagy can lead to 
cell death. 
 In this multistep process, autophagy substrates, such as cytoplasm and damaged 
organelles, are sequestered inside isolation membranes, which eventually mature 
into double-membrane structures called autophagosomes. Autophagosomes subse-
quently fuse with lysosomes to form autolysosomes where the sequestered compo-
nents are digested (Fig.  1 ) [ 7 ]. The molecular basis of autophagy was elucidated in 
autophagy-defective mutant yeasts [ 8 ]. The subsequent identiﬁ cation of vertebrate 
homologs greatly expanded our understanding of the molecular mechanisms of 
autophagy.
 Autophagy is driven by over 30 proteins (Atgs), which are well conserved from 
yeasts to mammals [ 7 ]. Atg1 [also called Unc51-like kinase 1 (Ulk1)] is a serine/
threonine kinase that is essential for the initiation of autophagy [ 9 ]. Autophagy is 
also regulated by phosphatidylinositol 3-kinase (PI3K) type III, which is a 
 component of a multi-protein complex that includes Atg6 (Beclin1). PI3K promotes 
invagination of the membrane at domains rich in phosphatidylinositol-3-phosphate, 
which are called omegasomes, thereby initiating the generation of the isolation 
membrane [ 10 ]. The subsequent expansion and closure of isolation membranes are 
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mediated by two ubiquitin-like conjugation pathways: the Atg5–Atg12 pathway 
and the MAP–LC3 pathway [ 7 ]. In cells that lack these ubiquitin-like conjugation 
systems, such as Atg5- and Atg7-deﬁ cient cells, autophagosome formation is 
largely disrupted, which indicates the necessity for Atg5 and Atg7 in autophagy. 
Ubiquitin-like conjugation of phosphatidylethanolamine to LC3 facilitates the 
translocation of LC3 from the cytosol to the sites of origin of the autophagic mem-
brane. This form of translocation is recognized as a reliable marker of autophagy. 
 Alternative Macroautophagy 
 Although Atg5 has long been considered as an essential molecule for autophagy, we 
recently identiﬁ ed an Atg5-independent type of autophagy, which is induced when 






















 Fig. 1  Hypothetical model of macroautophagy. There are at least two modes of macroautophagy, 
i.e., conventional and alternative macroautophagy. Conventional macroautophagy depends on 
Atg5 and Atg7, is associated with LC3 modiﬁ cation, and may originate from ER-mitochondria 
contact membrane. In contrast, alternative macroautophagy occurs independent of Atg5 or Atg7 
expression and LC3 modiﬁ cation. The generation of autophagic vacuoles in this type of macroau-
tophagy may originate from Golgi membranes and late endosomes (LE) in a Rab9-dependent 
manner. Although both of these processes lead to bulk degradation of damaged proteins or organ-
elles by generating autolysosomes, they seem to be activated by different stimuli in different cell 
types and have different physiological roles 
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Atg5-independent autophagic structures is indistinguishable from that of those 
formed during Atg5-dependent autophagy, i.e., isolation membranes, autophago-
somes, and autolysosomes [ 11 ]. Thus, we designated this form of Atg5-independent 
autophagy as “alternative macroautophagy” (Fig.  1 ). This alternative macroautoph-
agy is driven by Ulk1 and PI3K complexes during the initiation steps. These mole-
cules also function during the initiation of conventional autophagy. However, this 
pathway is not mediated by other components such as Atg9 and proteins in the 
ubiquitin-like protein conjugation system (Atg5, Atg7, and LC3), which extend 
conventional autophagic membranes. Alternative macroautophagy requires the 
extension of autophagic membranes, thus several unidentiﬁ ed molecules may 
mediate this function. 
 Alternative macroautophagy is not an atypical form of autophagy because it 
occurs in a wide variety of cells, including embryonic ﬁ broblasts and thymocytes, 
as well as in several tissues such as the heart, brain, and liver [ 11 ]. Erythrocyte 
maturation is a representative example of a physiological alternative macroautoph-
agy. Erythrocytes undergo enucleation and clearance of mitochondria during termi-
nal differentiation, and the possible involvement of autophagy in the latter process 
was proposed on the basis of a morphological analysis. However, the maturation 
process is normal in Atg5-deﬁ cient erythrocytes. In agreement, an ultrastructural 
analysis showed that mitochondria are also engulfed and digested by autophagic 
structures in both the wild-type and Atg5-deﬁ cient reticulocytes. These results indi-
cate that conventional macroautophagy does not eliminate mitochondria from 
erythrocytes. In contrast, mitochondrial clearance is signiﬁ cantly reduced in 
Ulk1- deﬁ cient reticulocytes where alternative macroautophagy is absent. These data 
suggest that Ulk1-mediated alternative macroautophagy plays a pivotal role in the 
elimination of mitochondria from erythrocytes [ 12 ,  13 ]. Ongoing research should 
provide a more detailed picture of the physiological and pathological relevance of 
alternative macroautophagy in the near future. 
 Autophagic Cell Death 
 Autophagy is activated by most cellular stressors, thus numerous autophagy- 
containing cells are often observed in regions where cell death occurs (Fig.  2 ). In 
most cases, autophagy has a cell protection function against cellular stressors, but 
autophagy is utilized as a cell-suicide mechanism in some cases [ 5 ]. Certain modes 
of cell death that are accompanied by protective autophagy are not referred to as 
“autophagic cell death.” In particular, the term “autophagic cell death” should be 
used when cell death is performed via autophagy activation. This can be demon-
strated by the suppression of cell death by autophagy inhibitors (e.g., 3-methyl 
adenine and wortmannin) or by the genetic ablation of autophagy (e.g., knockout or 
siRNA silencing of essential autophagy genes). If autophagy inhibition does not 
prevent cell death, this process should not be referred to as autophagic cell death.
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 Autophagic cell death occurs in several distinct settings. First, caspase- independent, 
autophagy-dependent PCD occurs during mammalian embryogenesis. Second, 
autophagy may induce developmental cell death during regression of the salivary 
glands in  Drosophila [ 14 ]. Third, autophagy-mediated cell death is induced in apop-
tosis-resistant cells, particularly in the absence of the pro-apoptotic proteins Bax 
and Bak [ 5 ]. The latter situation should provide an excellent experimental system 
for investigating autophagic cell death because the process can be observed at the 
cellular level. 
 Bax/Bak-deﬁ cient cells do not undergo apoptosis after exposure to a variety 
of apoptotic stimuli, although these cells still die in numerous autophagic struc-
tures (Fig.  2 ). This type of cell death is inhibited by autophagy inhibitors or by 

















 Fig. 2  Molecular mechanism of apoptosis and autophagic cell death. An increase in the permea-
bility of the outer mitochondrial membrane is crucial for apoptosis to occur and is regulated by 
multidomain pro-apoptotic members of the Bcl-2 family (Bax and Bak), resulting in the release of 
cytochrome c into the cytoplasm. Then, cytochrome c associates with Apaf-1, which activates the 
caspase cascade to execute apoptotic cell death. Apoptosis-associated mitochondrial membrane 
permeability is primarily controlled by Bcl-2 family members. When apoptosis is blocked, various 
apoptotic stimuli activate autophagy, resulting in the induction of autophagic cell death 
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is required for the death of Bax/Bak-deﬁ cient cells after exposure to apoptotic 
stimuli [ 5 ]. Although we discovered Atg5-independent alternative autophagy, it is 
not involved in the autophagic cell death of Bax/Bak-deﬁ cient cells. However, this 
does not necessarily indicate that alternative autophagy is irrelevant for autophagic 
cell death. In other situations, alternative autophagy may potentially induce autophagic 
cell death. 
 Cancer and Autophagic Cell Death 
 It has been suggested that autophagic cell death may participate in physiological 
and pathological events. A large body of evidence indicates that inhibition of apop-
tosis is critical for tumorigenesis, but the elimination of cancer cells may also be 
mediated by autophagic cell death, and there is evidence that decreased autophagic 
activity is related to tumorigenesis. For example, the levels of Beclin-1 (Atg6) are 
lower in some types of cancers of the ovary, breast, and prostate because of monoal-
lelic mutations [ 15 ]. Furthermore, mice that are heterozygous for the  beclin-1 gene 
are cancer prone [ 15 ,  16 ], which strongly suggests that inhibition of Beclin-1 
expression contributes to the pathogenesis of cancer. Moreover, Atg5, LC3, and 
Fip200 are associated with myeloma, glioblastoma, and breast cancer, respectively 
[ 17 ,  18 ], thereby suggesting that the failure of cells to undergo autophagy leads to 
tumor progression. 
 Several mechanisms may explain how tumorigenesis is mediated by the failure 
of cells to undergo autophagy: (1) accumulation of p62, a substrate of autophagy, 
leads to NF-κB activation [ 19 ]; (2) accumulation of p62 stabilizes Nrf2, which 
makes tumor cells resistant to hypoxic stress [ 20 ]; (3) retention of damaged organ-
elles, including mitochondria, increases the level of active oxygen species and 
increases the mutation rate; and (4) defective elimination of cancer cells due to the 
loss of autophagic cell death [ 21 ]. These mechanisms may be cell- and stimulus- type 
speciﬁ c; however, we believe that it is reasonable to conclude that the failure of 
autophagic cell death is one of the most crucial mechanisms involved in tumorigen-
esis because autophagic cell death occurs in normal cells (e.g., ﬁ broblasts or thymo-
cytes) but not in most cancer cells. Furthermore, in some cancer cells, the magnitude 
of JNK activation, which is a crucial factor for autophagic cell death, is signiﬁ cantly 
lower compared with that in normal cells after exposure to apoptotic stimuli [ 21 ]. 
In these cancer cells, the JNK activity level may not reach the threshold level 
required to induce autophagic cell death. This conclusion is supported by evidence 
that the enforced expression of activated JNK in cancer cells induces autophagic 
cell death. Taken together, it is likely that insufﬁ cient activation of JNK followed by 
the failure of autophagic cell death may induce uncontrolled growth of cells, which 
ultimately acquire the malignant phenotype. 
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 Many molecularly targeted anticancer agents have been developed on the basis of 
apoptosis. However, autophagic cell death is also involved in the mechanisms of 
carcinogenesis. Therefore, we speculate that cancer may be cured by inducing 
autophagic death in cancer cells. This type of treatment would be effective for can-
cers that do not respond to existing anticancer agents (i.e., agents with apoptosis- 
based mechanisms of action). In addition, synergistic effects with existing anticancer 
agents are expected. Thus, we are now trying to develop molecularly targeted anti-
cancer agents based on the induction of autophagic cell death. To meet this objec-
tive, we have established a high-throughput assay system that can monitor excessive 
autophagy and cell death–inducing activity. Using this assay, we screened a low 
molecular weight compound library to identify chemicals with autophagic cell 
death–inducing activities and successfully identiﬁ ed 24 candidate compounds. In 
particular, four of these compounds exhibited strong anticancer activities. At pres-
ent, we are optimizing these compounds for development as drugs based on phar-
macokinetic investigations and structure–activity relationships. In the near future, 
we aim to develop anticancer agents that will be effective against cancers that are 
resistant to the anticancer agents used in current clinical practice. 
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